Idiotypic Immune Targeting of Multiple Myeloma

References

• Barlogie, B., Jagannath, S., Desikan, K. R., et al. (1999). Total therapy with tandem transplants for newly diagnosed multiple myeloma, Blood, 93, 55–65.
   PubMed Web of Science ®Google Scholar
• Gieseler, F. and Nussler, V. (1998). Cellular resistance mechanisms with impact on the therapy of multiple myeloma, Leukemia, 12, 1009–1012.
   PubMed Web of Science ®Google Scholar
• Govindarajan, R., Jagannath, S., Flick, J. T., et al. (1996). Preceding standard therapy is the likely cause of MDS after autotransplantation for multiple myeloma, Brit. J. Haematol., 95, 349–353.
   PubMed Web of Science ®Google Scholar
• Verdonck, L. F., Lockhorst, H. M., Dekker, A. W., Nieuwenhuis, H. K. and Petersen, E. J. (1996). Graft-versus-myeloma effect in two cases, Lancet, 347, 800–801.
   PubMed Web of Science ®Google Scholar
• Aschan, J., Lonnqvist, B., Ringd., N. O., Kumlien, G. and Gajrtpm, G. (1996). Graft-versus-myeloma effect, Lancet, 346, 348.
   Google Scholar
• Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J., Thomas, L. L. M. and Verdonck, L. F. (1997). Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation, Blood, 90, 4206–4211.
   PubMed Web of Science ®Google Scholar
• George, A. J., Tutt, A. L. and Stevenson, F. K. (1987). Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1, J. Immunol., 138, 628–634.
   PubMed Web of Science ®Google Scholar
• Wilson, A., George, A. J. T., King, C. A. and Stevenson, F. K. (1990). Recognition of a B cell lymphoma by anti-idiotypic T-cells, J. Immunol., 145, 3937–3943.
   PubMed Web of Science ®Google Scholar
• Campbell, M. J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J. B., Levy, S. and Levy, R. (1987). Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumorderived immunoglobulin M and its molecular subunits, J. Immunol., 139, 2825–2833.
   PubMed Web of Science ®Google Scholar
• Kwak, L. W., Young, H. A., Pennington, R. W. and Weeks, S. D. (1996). Vaccination with syngeneic lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colon stimulating factors primes mice to a protective T-cell response, Proc. Natl. Acad. Sci. USA, 93, 10972–10978.
   PubMed Web of Science ®Google Scholar
• King, C. A., Spellerberg, M. B., Zhu, D., Rice, J., Sahota, S. S., Thompsett, A. R., Hamblin, T. J., Radl, J. and Stevenson, F. K. (1998). DNA vaccines with single-chain FV fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma, Nat. Med., 4, 1281–1286.
   PubMed Web of Science ®Google Scholar
• Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A. and Levy, R. (1992). Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors, New Engl. J. Med., 327, 1209–1215.
   PubMed Web of Science ®Google Scholar
• Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engelman, E. G. and Levy, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nat. Med., 2, 52–58.
   PubMed Web of Science ®Google Scholar
• Osterborg, A., Yi, Q., Bergenbrandt, S., Holm, G., Lefvert, A. and Mellstedt, H. (1995). Idiotypic-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests, Br. J. Haematol., 89, 110–116.
   PubMed Web of Science ®Google Scholar
• Kwak, L. W., Taub, D. D., Duffey, P. L., Bensinger, W. I., Bryant, E. M., Reynolds, C. W. and Longo, D. L. (1995). Transfer of myeloma idiotypic-specific immunity from an actively immunised marrow donor, Lancet, 345, 1016–1020.
   PubMed Web of Science ®Google Scholar
• Bergenbrant, S., Yi, Q., Osterborg, A., et al. (1996). Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients, Brit. J. Haematol., 92, 840–846.
   PubMed Web of Science ®Google Scholar
• Osterborg, A., Yi, Q., Henriksson, L., et al. (1998). Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, Major Histocompatibility Complex-restricted, CD8- and CD4-specific T-cell responses, Blood, 91, 2459–2466.
   PubMed Web of Science ®Google Scholar
• Massaia, M., Borrione, P., Battaglio, S., et al. (1998). Tumor-specific immune responses elicited by idiotype vaccines in multiple myeloma: Detection by delayed-type hypersensitivity (DTH) skin tests, Blood, 92(Suppl. 1), 280b.
   Google Scholar
• Romani, N., Gruner, S., Brang, D., et al. (1994). Proliferating dendritic cell progenitors in human blood, J. Exp. Med., 180, 83–93.
   PubMed Web of Science ®Google Scholar
• Wen, Y. J., Ling, M., Bailey-Wood, R. and Lim, S. H. (1998). Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma, Clin. Cancer Res., 4, 957–962.
   PubMed Web of Science ®Google Scholar
• Lim, S. H. and Bailey-Wood, R. (1999). Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma, Int. J. Cancer (in press).
   Google Scholar
• Cull, G., Durrant, L., Haynes, A. and Russell, N. (1998). Generation of idiotype-specific immune responses following vaccination with autologous paraprotein-pulsed dendritic cells in myeloma, Blood, 92(Suppl, 1), 275b.
   Google Scholar
• Mackenzie, M., Strang, G., Peshwa, M., Sopapan, J. and Valone, F. (1998). Phase I/II trial of immunotherapy with idiotype-loaded autologous dendritic cells (APC8020) for refractory multiple myeloma, Blood, 92(Suppl. 1), 108a.
   PubMedGoogle Scholar
• Reichardt, V. L., Okada, C. Y., Liso, A., et al. (1999). Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study, Blood, 93, 2411–2419.
   PubMed Web of Science ®Google Scholar
• Shimizu, K., Fields, R. C., Giedlin, M. and Mule, J. J. (1999). Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines, Proc. Natl. Acad. Sci. USA, 96, 2268–2273.
   PubMed Web of Science ®Google Scholar
• Roskrow, M. A., Dilloo, D., Suzuki, N., Zhong, W., Rooney, C. M. and Brenner, M. K. (1999). Autoimmune disease induced by dendritic cell immunization against leukemia, Leuk. Res., 23, 549–557.
   PubMed Web of Science ®Google Scholar
• Jung, S. and Schluesener, H. J. (1991). Human T-lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins, J. Exp. Med., 173, 273–276.
   PubMed Web of Science ®Google Scholar
• Gjertsen, M. K., Bakka, A., Breivik, J., et al. (1995). Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation, Lancet, 346, 1399–1400.
   PubMed Web of Science ®Google Scholar
• Gjertsen, M. K., Bjorheim, J., Saeterdal, I., Myklebust, J. and Gaudernack, G. (1997). Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12 val) peptide vaccination of a patient, recognize 12val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation, Int. J. Cancer, 72, 784–790.
   PubMed Web of Science ®Google Scholar
• Treon, S. P., Mollick, J. A., Urashima, M., et al. (1999). Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone, Blood, 93, 1287–1298.
   PubMed Web of Science ®Google Scholar
• Lim, S. H., Austin, S., Owen-Jones, E. and Robinson, L. (1999). Expression of testicular genes in haematological malignancies, Brit. J. Cancer (in press).
   Google Scholar
• Tureci, O., Sahin, U., Zwick, C., Koslowski, M., Seitz, G. and Pfreundschuh, M. (1998). Identification of a meiosisspecific protein as a member of the class of cancer/testis antigens, Proc. Natl. Acad. Sci. USA, 95, 5211–5216.
   PubMed Web of Science ®Google Scholar